William Looney

What is industry icon Fred Hassan's management formula for staying fresh in an era of market churn?

Last month's decision by India's Supreme Court to deny a patent for the top-selling oncologic drug Glivec took nearly a decade of litigation to resolve—but the implications in and beyond India are both immediate and lasting.

Pharm Exec's annual look at the trends and best practices in biopharm licensing and M&A for the year ahead.

The conversation thread that binds this month's Pharm Exec is building communities—when the harsh economics of market change suddenly discounts the familiar, then the best way to move up is to reach out.

Pharm Exec's 35-member Editorial Advisory Board met last month to discuss a range of topics, including the influence of other business sectors on pharma's global strategy.

Pharm Exec recently convened a cross-section of industry experts to review current and pending efforts to turn great science into good oncology practice.

Today's most important public health story is the advance in our understanding of the biology of cancer, writes Pharm Exec Editor-in-Chief William Looney.

As companies seek safety from empowered payers, bankrupt governments, and distracted regulators, success will come to those who understand how competition and technology are changing the way everything this industry does.

Promoting the merits of private-sector drug innovation is no easy task—just ask the UK's Office of Health Economics, with a record 50 years of engagement around the hard policy questions that ultimately drive success in the pharmaceutical marketplace.